What Does It Take to Build a GLP-1 and Peptide Manufacturing Facility?

GLP-1 medicines have moved from specialist pharmaceutical discussions into the mainstream. Medicines such as Ozempic, Wegovy, Mounjaro and Zepbound have brought peptide-based therapies into sharper focus. Beyond their established uses in managing type 2 diabetes and obesity, research is examining their potential role in other health conditions, while certain medicines have also received additional approvals for specific indications.

The expanding use of these medications is creating new opportunities for pharmaceutical manufacturers. Industry projections suggest that global demand for GLP-1 peptide APIs could reach approximately 99,000 kilograms annually by 2030. For pharmaceutical manufacturers, this creates a need to plan production capacity, process capabilities and regulatory compliance together, while allowing for future expansion.

So, what does it take to build a GLP-1 and peptide manufacturing facility that is ready for production and accommodates future growth?

1. Understanding the manufacturing scope

Not every peptide manufacturing facility has the same requirements. Before planning begins, manufacturers need to establish which stages of production the facility will handle.

• API manufacturing: Peptide synthesis, purification, isolation and drying, as required by the selected manufacturing process. The facility design must accommodate the relevant process equipment, solvent handling, material flows and safety controls.
• Sterile fill-finish: Preparation of the formulation, product-specific sterilisation or sterile filtration where applicable, aseptic filling into suitable containers such as vials or cartridges, followed by inspection and packaging.
• Integrated manufacturing: Combining API production and fill-finish within one facility, either from the outset or through a phased expansion.

Each approach has different space, utility, equipment, safety and compliance requirements. Defining the scope and target capacity early helps establish a realistic project plan and reduces the risk of costly design changes later.

2. Plan the pharmaceutical facility around the process

A well-designed pharmaceutical manufacturing facility begins long before construction. Site selection, capacity planning, process flow, project budget and future expansion plans all influence the final design.

The layout must account for the movement of personnel, materials, products and waste while minimising contamination and cross-contamination risks. Pharmaceutical facility design must consider cleanroom zoning, pressure differentials and airflow patterns according to the processes being carried out.

Future expansion planning should consider not only available space but also utility capacity, equipment access, process flows and the potential impact of modifications on ongoing operations.

3. Engineer pharmaceutical cleanrooms, HVAC and utilities

For sterile injectable manufacturing, environmental control is central to contamination prevention. Pharmaceutical cleanroom design must account for cleanroom classifications, qualification, pressure cascades, air filtration, airflow patterns and environmental monitoring provisions according to the manufacturing process and applicable regulatory requirements.

EU GMP Annex 1, which addresses the manufacture of sterile medicinal products, places significant emphasis on a comprehensive contamination control strategy. This strategy should bring together facility and equipment design, personnel and material flows, cleaning and disinfection, process controls, monitoring and other relevant measures into a documented, risk-based approach.

Pharmaceutical HVAC systems and utilities must be designed around the manufacturing process, required quality attributes and planned production capacity. Depending on the application, these may include purified water, Water for Injection (WFI), clean steam, compressed air, nitrogen, chilled water and suitable waste-treatment systems. Their specifications, capacity and monitoring requirements should be established during process and facility design.

Storage requirements vary across peptide APIs, intermediates and finished products. Temperature-controlled storage, including refrigerated or frozen conditions where required, should be planned according to the material’s stability data and specified storage conditions.

4. Address process safety and equipment integration

Peptide API manufacturing may involve significant quantities of organic solvents and process chemicals, along with specialised equipment. Depending on the process and materials handled, the facility may require appropriate solvent storage and transfer systems, ventilation, hazardous-area classification, solvent recovery and waste-handling arrangements.

Where potent or otherwise hazardous substances are handled, containment and exposure-control measures should be established through a documented risk assessment.

Equipment selection and integration should follow the defined manufacturing process. Depending on the facility scope, this may include peptide synthesis systems, purification and chromatography equipment, drying systems or lyophilisers, formulation vessels, filling lines and appropriate aseptic-processing technologies such as isolators or Restricted Access Barrier Systems (RABS).

Their footprints, service connections, maintenance access and installation requirements need to be considered early. Late changes to equipment specifications can affect layouts, utilities, project costs and delivery schedules.

5. Build GMP compliance and qualification into the project

A completed building is not necessarily a production-ready facility. GMP-compliant pharmaceutical manufacturing requires qualification and validation activities to be planned alongside engineering and construction, demonstrating that facilities, equipment and utilities are suitable for their intended use.

Documentation, qualification protocols and acceptance criteria should be established early in the project. This helps create a traceable record of design decisions, installation checks and system performance, supporting regulatory compliance and inspection preparedness.

Qualification of facilities, utilities and equipment should be coordinated with process validation, cleaning validation and other applicable validation activities, according to the manufacturing scope and regulatory requirements.

Building Management Systems (BMS), environmental monitoring systems and relevant quality-system interfaces should also be considered during planning. The objective is to establish a facility that can demonstrate control over its processes and support regulatory inspections in the markets it intends to serve.

Applicable GMP requirements and regulatory expectations depend on the product, manufacturing activities and target markets. These may include relevant US FDA cGMP regulations and guidance, EU GMP requirements, WHO GMP guidance and applicable national regulations.

6. Improve project execution without compromising quality

As demand grows, manufacturers face increasing pressure to bring new capacity online. Faster execution, however, must come from better planning, coordination and execution, not from bypassing essential engineering, qualification or validation activities.

Phased construction and modular pharmaceutical cleanroom solutions may help accelerate project execution when design, procurement and installation activities are coordinated effectively. The extent of any time savings will depend on the project scope, site conditions, equipment integration and qualification requirements.

A turnkey pharmaceutical facility approach can help streamline project delivery by coordinating design, cleanrooms, HVAC, utilities, equipment interfaces and agreed qualification activities through a clearly defined project scope. This can reduce coordination gaps, clarify responsibilities and improve visibility across project milestones.

Building a GLP-1 manufacturing facility for today’s demand and tomorrow’s growth

Planning a GLP-1 or peptide manufacturing facility means creating infrastructure that supports the intended process, meets applicable regulatory requirements and allows for future expansion.

At Fabtech Technologies, we approach pharmaceutical facilities as integrated systems. From concept development and pharmaceutical facility design to cleanrooms, HVAC, utilities, equipment integration and qualification, every element must work together to support the intended manufacturing process. Qualification and validation requirements are considered as part of overall project planning, according to the agreed scope.

Where Fabtech Adds Value

Integrated project delivery: Coordinating facility design, cleanrooms, HVAC, utilities and equipment interfaces to streamline execution and clarify project responsibilities.

Planned for future expansion: Considering additional production lines, equipment changes and capacity requirements early in the design process.

Compliance-focused engineering: Incorporating applicable GMP requirements, documentation and qualification needs into project planning from the outset.

Execution efficiency: Evaluating modular cleanroom solutions and phased construction where they align with project requirements and can support efficient delivery.

Planning a GLP-1 or peptide manufacturing facility?

Connect with Fabtech Technologies to discuss your project scope, engineering requirements and the right way to plan your next phase of growth.